Chicago Treatment Options Conference Open for Free Registration
The Leukemia Research Foundation (LRF) is working with Loyola University Health System and Be The Match to host a free conference on Saturday, June 14, 2014 for leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes (MDS) patients and caregivers.
The conference will be held at:
Belvedere Events and Banquets
1170 W. Devon Avenue
Elk Grove Village, Ill
It begins at 7:30 a.m. and runs through 12:45 p.m.
Parking, continental breakfast and lunch are provided, free of charge.
How Will Attending This Help Me?
If you're local and can attend, this conference offers patients, caregivers, advocates and loved ones the opportunity to:
- Learn more about your specific disease
- Learn more about current treatments and emerging therapies
- Put your questions to an expert physicians panel
- Hear from others also coping with blood cancer
- Hook up with a support network
What's On the Agenda?
Here's how they'll roll:
Dr. Parameswaran Venugopal from Rush University Medical Center will discuss Chronic Lymphocytic Leukemia (CLL).
Dr. Todd Zimmerman from the University of Chicago Medicine will discuss Multiple Myeloma.
Dr. Willis Navarro of the National Marrow Donor Program will discuss "Approaches for Increasing Transplant for 'Donor-less' Patients".
Dr. Patrick Stiff of Loyola University Medical Center will discuss "Advances in Bone Marrow Transplantation".
Dr. Damiano Rondelli of the University of Illinois Medical Center at Chicago will discuss Myelodysplastic (MDS) and Myelofibrosis Syndromes.
Dr. Olga Frankfurt of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University will discuss Acute Myelogenous Leukemia (AML).
And Dr. Scott Smith of Loyola University Medical Center will discuss "New Targeted Therapies for Non-Hodgkin's Lymphoma (NHL)".
During the scheduled lunch time, a physician panel will open featuring all presenting doctors during which time patients can ask questions.
Click HERE for more information on the conference and where to register.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
